Early Heart-Kidney drug trial halted
NCT ID NCT06639087
Summary
This early-stage study aimed to test the safety and effects of an experimental drug called AZD5462 when added to a standard heart failure medication (dapagliflozin). It involved a small group of people who had both heart failure and moderate kidney impairment. The study was terminated early, and its main goal was to see how the body processes the drug and if it affects things like salt levels in urine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sofia, 1612, Bulgaria
Conditions
Explore the condition pages connected to this study.